Showing results (71-80 of 676) with videos related to
Sort By:
Pageof 68
Journal of the Neurological Sciences|March 30, 2007
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosisOliver Neuhaus, Bernd C Kieseier, Hans-Peter HartungMultiple Sclerosis (Houndmills, Basingstoke, England)|October 26, 2014
Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosisHans-Peter Hartung, Orhan Aktas, Alexey N BoykoJournal of Neural Transmission (Vienna, Austria : 1996)|June 25, 2013
Biotherapeutics for the treatment of multiple sclerosis: hopes and hazardsClemens Warnke, Bernd C Kieseier, Hans-Peter HartungNature Reviews. Neurology|June 17, 2010
Fingolimod is a potential novel therapy for multiple sclerosisOrhan Aktas, Patrick Küry, Bernd Kieseier, et al.Neurology|December 25, 2002
Immune mechanisms in chronic inflammatory demyelinating neuropathyBernd C Kieseier, Marinos C Dalakas, Hans-Peter HartungCurrent Opinion in Neurology|April 16, 2019
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigmBruce A C Cree, Jan Mares, Hans-Peter HartungAnnals of Neurology|April 27, 2011
The complex world of oligodendroglial differentiation inhibitorsDavid Kremer, Orhan Aktas, Hans-Peter Hartung, et al.Current Neurology and Neuroscience Reports|April 15, 2003
New immunopathologic insights into multiple sclerosisBernhard Hemmer, Bernd Kieseier, Sabine Cepok, et al.Current Opinion in Neurology|June 8, 2022
New drugs for multiple sclerosis: new treatment algorithmsBruce A C Cree, Hans-Peter Hartung, Michael BarnettBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 4, 2019
Monoclonal Antibodies for Multiple Sclerosis: An UpdateJonas Graf, Orhan Aktas, Konrad Rejdak, et al.Pageof 68